A new proposal for phenotypic classification and outcome assessment of dermatomyositis based on clinical manifestations and serological testing

• Published in: Anais brasileiros de dermatología 2024-05, Vol.99 (3), p.342-349
• Main Authors: Huang, Ting, Ding, Ting, Ding, Liqing, Xie, Shasha, Li, Xiaojing, Meng, Qiming, Wu, Xiaomeng, Luo, Hui, Zhao, Hongjun
• Format: Article
• Language: English
• Subjects: Adult; Aged; Autoantibodies - blood; Classification; Cluster Analysis; Cohort studies; DERMATOLOGY; Dermatomyositis; Dermatomyositis - blood; Dermatomyositis - classification; Dermatomyositis - diagnosis; Dermatomyositis - pathology; Female; Health care; Humans; Interferon-Induced Helicase, IFIH1 - immunology; Interstitial lung disease; Lung Diseases, Interstitial - classification; Lung Diseases, Interstitial - diagnosis; Male; Middle Aged; Original; Outcome assessment; Outcome Assessment, Health Care; Phenotype; Retrospective Studies; Serologic Tests; Severity of Illness Index
• ISSN: 0365-0596; 1806-4841; 1806-4841
• DOI: 10.1016/j.abd.2023.06.005

Dermatomyositis (DM) is an infrequent disease subgroup of idiopathic inflammatory myopathies characterized by distinct skin lesions. However, high heterogeneity makes clinical diagnosis and treatment of DM very challenging. Unsupervised classification in DM patients and analysis of key factors related to clinical outcomes. This retrospective study was conducted between 2017 and 2022 at the Department of Rheumatology, Xiangya Hospital, Central South University. 162 DM patients were enrolled for unsupervised hierarchical cluster analysis. In addition, we divided the clinical outcomes of DM patients into four subgroups: withdrawal, stabilization, aggravation, and death, and compared the clinical profiles amongst the subgroups. Out of 162 DM patients, three clusters were defined. Cluster 1 (n = 40) was mainly grouped by patients with prominent muscular involvement and mild Interstitial Lung Disease (ILD). Cluster 2 (n = 72) grouped patients with skin rash, anti-Melanoma Differentiation Associated protein 5 positive (anti-MDA5+), and Rapid Progressive Interstitial Lung Disease (RP-ILD). Cluster 3 (n = 50) grouped patients with the mildest symptoms. The proportion of death increased across the three clusters (cluster 3 < cluster 1 < cluster 2). The number of cases was limited for the subsequent construction and validation of predictive models. We did not review all skin symptoms or pathological changes in detail. We reclassified DM into three clusters with different risks for poor outcome based on diverse clinical profiles. Clinical serological testing and cluster analysis are necessary to help clinicians evaluate patients during follow-up and conduct phenotype-based personalized care in DM.